call Bob, everyone XXXX Thanks, welcome discuss highlights. financial our our quarter and results to operating to first and conference
virtually Parker, Chief Chief during Levine, today Operating President, Hesterberg, our Sundar, Officer; Lyndal are our Doug Chief and question-and-answer Ms. these Science our be Officer; Officer; our available Al Medical Vice mostly Padma Dr. Financial will folks session. me Senior Joining Ross, our Commercial. All Officer; Dr. the Chief
start to commitment and our quarter of through amazing Thanks the to say hear and call have being to environmental the encouraged we the as made in macro strategy pivoting today, now we sacrifice are able face considerable current have the beginning on that our call even XXXX, company’s unparallel mission as the you’ll to today’s I’m continued of progress headwinds. first very team, momentum significant our rollout and
or to exciting Medicare I cell coverage Medicaid identification are or services call Xa first most for responsive likely and centers under recent chemotherapy. is predictive patients our to of DetermaRx, lung think with X non-squamous big at risk for the and the small who Stage test cancer only local for With program. and surgery adjuvant following for our what the of recurrence determination final CMS for DetermaRx announcement LCD we news
LCD towards follow players CMS milestone national stage for The will will to final up is We coverage significant a securing lung anticipate broad for reimbursement regional and we to Medicare patients. LCD of and that the this decision. cancer final nationwide believe early XX% DetermaRx lead several eligible
with have Our coverage goal the is for next efforts Medicare our follow coverage that insurance. securing to patients historically with step intensity who payers private decisions of private
positive feedback lives, date, healthcare additional plans XXX covered represent evidence see that our the commercial and million to reaching out on over very supporting our have efforts To we already test. included will
June, LCD. holding been new our marks for in run test era submit a to while final we waiting we’ve Importantly, This invoices the for CMS will OncoCyte.
We’re now molecular proudly positioned as reimbursement. secured high-value diagnostics player innovative an in with
is the the XX% recurrence DetermaRx important patients critical new reminder, high brief early for likelihood have lung a be identifying need addresses that surgery. test to curative unmet of stage is what who a an to As having despite cancer of XX% supposed
XX% clinical with by risk as Most surgery chemotherapy of importantly, survival treated had rate rate study, high high-risk in a patients a a survival untreated who and XX%. test only post of published identified compared DetermaRx to five-year had patients
for the With cancer these number outcomes of dramatically striking potential early results, it improve that stage this has large to test lung a is clear patients.
active Traditionally, many given cancelled we season. format as to either of we presentations year the conventions due COVID-XX. work spring to or was submitted their team and our moved with that the conference medical accepted. associations have this very virtual But Obviously, of number expected, an disappointing a is medical were for abstracts this
abstract the an have for at ATS to an Thoracic or proud presentation oral American Society International Conference. XXXX DetermaRx selected were for We
the published However, that included abstract one focused and follow-up from data XXX long-term meetings the health, was study was The that of and on cancelled of by DetermaRx a ATS year. this the patients. of was economic impact
of testing had scans with one through three XX% a were of XX% DetermaRx two patients of associated with their and experienced as patients recurrence their and these patients as that years showed within stress closely resources. be testing of can of risk untreated It costly surgery, radiologic inefficient frequent risk patient followed did DetermaRx patients low in cancer healthcare high not recur. These which risk identified recurrence are uses by identified low through
data patients low cancers for risk clinical are on up have These be DetermaRx reducing those also the patients XX% if possible recur limit very of thereby radiological having it would scan use overall can risk resources. they on that identifying to follow healthcare in but reduced Our the risk low little utility of rapidly frequency scan safely the surveillance cancer untreated, the of as impact reinforce high by which very follow may up to recurrence. that important annual of detection showed limiting data
to While progress our we’ve few the only with XX, expand Even DetermaRx that our I’m number continued pandemic, on was and new XX test. with ago, say to we’ve excited since our weeks of reach our ongoing the increased efforts XX. call to our March sites last our call a last short onboarding from
since large Network; states; impressive and community with our that primary XX health include at XX Healthcare, XX the is systems, more base Even and Dignity and Southern Health of onboarded sites were large these system Providence in the positions start like pandemic XX hospitals of healthcare clinics care Network. the
identify were who recurrence the that treatment changed of every drives of these at risk work impact the XX chemotherapy. is and addition day. potential To is type of course date, a harder risk life patients we this for the saved to what represents me their OncoCyte and now with patient high team Each
with and we distribution international Diagnostics Africa. expand agreement commercial announced recently will In an the DetermaRx addition, Middle of CORE availability which India, East into
one partner advanced thrilled the delivering Diagnostics in reference which labs clinical in growing and country. is with We’re fastest of to the expertise most testing CORE India techniques the
service menu Diagnostics U.S. be who proprietary the diagnostics test orders of U.S., existing beyond is offering. to by providing high on in areas. our Under an expand labs important customer test their with part into already run the in initially generating strategy with agreement, local An the the partnering oncologic value, OncoCyte and CORE the focused will are the terms of of delivery
countries. CORE, partnering is intention physicians the of other with plans XXX internationally just ordering sales with members as their X,XXX to in and South grow the with This Asia. gained extending By base we XX of in as geographies, to force oncology beginning access well our the distribution other of including of team parts America customer to
driving Novel test they to often require their even face plans were Now by as surgeries, adoption education adoption. COVID-XX our even to cancer affected is practice. clinicians. an I’ll delayed Extensive turn physicians and adoption since diagnostic increase component for our essential physician sometimes halted. patients, change efforts further challenges of
have reluctant chemo leave of heard and including or may as aid care immune COVID to undergo patients the surgery begin been in and anesthesiologists, physicians, them Many this to are patients recruited compromised. we’ve some surgeons
immediately onboarding we’ve engagement The for preparation in challenge shelter cancer time patients that, surgeries And ensure in as the program is done to as can much hospital virtual physician for because resume normally. we pivoted of when we for and to doesn’t place. a
online With enthusiasm, participants education programs. I in can physician X,XXX share that had we’ve over
treatment While eases. remain patients has to as cancer as aware challenges all virtual COVID remain in believe the in the the procedures a environment this We and situation they well us running life-saving expanded plan. healthcare very soon the patient population provide current an of positions on serve placed clarity system, of tests that foundation need on
cancer evaluates likely to identify patients PD-LX gene our or expression My immune microenvironment update next more on in or from profile the to that immune is biopsies individuals less test anti-PD-X respond therapy. DetermaIO, to
commercial validation for announced settings. last call, and our On and use research making only launch CLIA the of of we DetermaIO biopharma research available completion in for it other use our
a while to both for identify likely very therapies patients, who benefit and challenging still researchers. to patients pharma As is bit these it immunotherapy subset of for reminder, transformative is a for are cancer the from oncologists
believe more we to currently potential available compared accurate from benefit our on Based enable has of patients the treatment will DetermaIO biomarkers. data, prediction current to which
a potential select responders potentially side a them avoid that more that informed distinguishing occur give alternative is when choice can patients an by latent autoimmune from exacerbated immune disorder to By non-responders, we the allowing can effects likely therapies therapy.
response. management an will a who health sustained selection allow overall of cost will expensive important and save these Better patients of accurate therapies but have more
impact also brought have at immune which We market. such could DetermaIO, a on better real therapies biomarkers, believe that to the performing are as new speed
towards pharma X.X research that clinical patients X,XXX therapy market are designed the ongoing recognize trials for are immune a million there’s worldwide. and in to actively in over recruit opportunities well clinical large work we pursuing As we which approximately opportunity services the launch,
received numerous academic interested in signature. biomarker participating further pharma and We interest this are the in of have that groups study significant from
will cancer. data industry still TNBC, At this the form test of in breast incredible performance predicting now the breast this years. be cancer, meeting, American deadliest Society in the five we breast call more as cancer XXXX in despite progress XX% And the will virtual we date presenting within demonstrating cancer, die which Clinical to in the women of Oncology, of triple-negative made with than response is of ASCO
is be in our potentially cancer applications first patients lung DetermaIO States, TNBC treatment the potential below, very annually market tumor eligible types. more we our bit a data across detail significant. addressable could therapy for as explore other United for of immune outside begin the I’ll to XXX,XXX As With potential
to next biopsies. Moving in management lung aid our to nodules the help invasive CT-identified potentially development of lung to unnecessary test in DetermaDx, blood-based avoid
as cancer proprietary investors, approach our sensitive for the of new reminder interrogation utilizes early harnesses to biomarker. a immune DetermaDx As response that our a immune system’s presence system
currently are to on lab clinical the XXX of year, end study, samples COVID clinical approximately We our pandemic, we Despite prospectively remain the by serve this thanks team. conducting collected our track validation of blinded blood DetermaDx final the patient to the of QX testing clinical our validation validation dedication lab clinical as complete to in setting.
we submission as execution well availability Assuming final establishment for which success validation utility the clinical of clinical for and results parameters, as will the including commercial additional begin dossier is required of publication studies. preparation performance CMS
X.X associated We of and their the scans reduce can CT indeterminate XX% to estimated and be cases remain serious committed help of complications with serving pulmonologists to unnecessary patients annually. which biopsies, million
results able to complete studies be on blinded us we’ll the they comment clinical are June process. until calls, are revealed when late validation discussed we previous and As the to not on in thus
touch to acquisition which opportunity, services was our by Genetics. our pharma like I’d of Insight growing upon enabled
additional biopharma successful DetermaIO products boutique of the business contracts services to pharma acquisition continuing that customers. us the us with immediately lab pharma test, allows a of while meet Insight our to the Genetics proprietary addition to also a In services leverage certified into brought needs
companion drugs oncology enable companies developing We pharma to suite development stage excitingly of way in a clinical Our of indications. trial services with a through discovery built molecular development needed support and in several services full pharma a diagnostic support other global analysis to regulation in subsequent drug from the range broad pharma offerings for immunotherapies submission. pharma discussions and pipeline robust the are all
Genetics types. different therapies Insight development triple-negative has aid I product of As breast the potential has of tumor a called since the the management the to the mentioned announced immune DetermaIO cancer assay. in call we its It test across when origins unique in TNBCType acquisition,
and measures AR target five including that assay immune-therapy, of uses surgical inhibitors algorithm gene PARP XXX a or and is biopsy different TNBCType classify from proprietary receptors chemotherapy. to like therapies then subtypes with a the therapeutics, responses patients RNA and associated to specimen types into cytotoxic
more may to select believe beyond this and now the various in patients for note TNBC biopharmaceutical therapy that diagnostic RNA-based lay also development an TNBC at proprietary therapy target immune potential technology classifier therapeutics predictive the with appropriately did We companion to as foundation important DetermaIO. be It’s to the that for signature assay broadly important this our help actually for companies.
treatment very of with in a So in options. programs. for ongoing survival real XXX aggressive While rates patients why about effective TNBC significant still been is with this? and need we’re to those diagnosed so it with have improve breast cancer Because strides with discovery-phase breast five-year of over additional It’s cancer. there’s amount there of pharma clinical a form excited lower for this, and outcomes the less outcomes improving great focus triple-negative trials a cancer,
best may multiple important an eventually plan TNBCType clinical platforms. provide the treatment patients that believe therapeutic role for identifying these in We across
in the of While excited suite tests program the about as expanding as in sharing lung more forward develops. first we’re TNBCType development, beyond and of potential the clinical look to our the step incredibly of still reach cancer
necessary for of financials, I we of touch including review our and taken we personnel for steps to our distancing. minimize manage We’ve over a all maintain OncoCyte. small impacting essential COVID-XX contact to social our protect and labs deemed stage employees, Because to do our are early appropriate rotating in cancer, operations. the upon cases continue a pandemic number is to we the to the like how patient with Before patients turn call Mitch I’d
We’ve also related generating XXXX, on value not and main market our market months. have are made prioritized the given capital in uncertainty our on future reducing and three planned revisions for projects OpEx the that to next investments to projects, spend XX R&D
revenue CMS are; the Our other and our pharma the three, for one, dossier. growth; complete DetermaRx and DetermaIO validation Two, and launch contracts clinical and pharma continuing prepare projects. prioritized drive projects for pursuing DetermaDx to studies
shared to encouraged on be progress I’ve the As made we’ve today, by programs. we these exciting continue
previously due all anticipate do of shared our timelines. to not we we Importantly, any track on team, remain to our across dedication products. delays significant the tremendous And
hope clear actionable that strong continued After momentum answers toward providing our for today’s call, I we’ve it’s patients. cancer
our points to look for always the at reach exciting continued improve will underserved on promotional outcomes and We development will success new for the and decision on lookout front partnerships to that patients. expand
like Levine the financials. over I’d Mitch of for point, a to this call at review So turn Mitch? the to
